Pelacarsen
As of the edition of 20 October 2026, Pelacarsen is an oligonucleotide: in active development; acts on LPA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Oligonucleotide
- Registered trials
- 15, 1 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LPA | Apolipoprotein | P08519 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 1 |
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 5 | 1 | 4 | 0 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akcea Therapeutics | Lead sponsor of trials | 2015 to now |
| Novartis | Lead sponsor of trials | 2026 to now |